The report “Blood Screening Market by Technology (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting), Product (Instrument, Reagent) & End User (Blood Bank, Hospital) - Forecasts to 2019”, provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the blood screening market along with estimates and forecasts of the revenue and share analysis.

http://www.marketsandmarkets.com/Market-Reports/blood-screening-market-267747042.html
Early buyers will receive 10% customization on reports.

The blood screening market is a growing field that has witnessed a number of technological advancements since its inception, such as a shift from first-generation ELISA to advanced NAT technologies. This market is driven by several factors including increasing number of blood donations and blood donors, rising awareness regarding the safety of donated blood, increasing patient affordability, increasing adoption of NAT, and rising demand of donated blood. However, factors such as high capital expenditure and operating cost of NAT and stringent regulatory approval processes are likely to hinder the growth of this market. The blood screening market in Asia is likely to provide an array of opportunities owing to the growing demand for donated blood, increasing disposable income (leading to adoption of NAT ), and increased focus of key players in the Asian region.

Speak to analyst@ http://www.marketsandmarkets.com/speaktoanalyst.asp?id=267747042

North America dominated the blood screening market, with the U.S. accounting for a major market share. However, Asia is poised to grow at the highest CAGR during the forecast period. Increasing prevalence and incidence of infectious diseases, high demand for donated blood, and increased awareness among people regarding the safety of donated blood are driving the blood screening market in this region.

Download PDF brochure@ http://www.marketsandmarkets.com/pdfdownload.asp?id=267747042

Prominent players in this market are Grifols (Spain), Roche Diagnostics (Switzerland), Abbott Laboratories (U.S.), bioMérieux (France), Bio-Rad Laboratories, Inc. (U.S.), Siemens Healthcare (Germany), Ortho Clinical Diagnostics, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.) and Beckman Coulter (U.S.).